NasdaqGM:HROWPharmaceuticals
Opaleye Trims Harrow Stake After Earnings Miss While Debt Risk Rises
10% owner Opaleye Management recently sold nearly 200,000 Harrow shares shortly after the latest earnings release.
The transaction was an indirect insider sale, but Opaleye still holds close to a 10% stake in Harrow.
The sale follows a period of increased share price volatility and draws attention to insider activity at NasdaqGM:HROW.
Harrow, traded on NasdaqGM:HROW, recently closed at $35.38 after a 33.0% decline over the past month and a 29.1% decline year to date. Even with this...